Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Etoposide pharmacology.

K R Hande1

  • 1Vanderbilt University School of Medicine, Nashville, TN.

Seminars in Oncology
|December 1, 1992
PubMed
Summary
This summary is machine-generated.

Etoposide is an effective anticancer drug that works by breaking cancer cell DNA. Research is exploring how to optimize its dosing by studying its pharmacokinetics and patient variability.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cytidine and deoxycytidylate deaminase inhibition by uridine analogs.

Biochemical pharmacology·2010
Same author

A phase I trial of outpatient weekly docetaxel and concurrent radiation therapy for stage III unresectable non small-cell lung cancer: a Vanderbilt Cancer Center Affiliate Network (VCCAN) Trial.

Clinical lung cancer·2004
Same author

Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer.

Clinical breast cancer·2002
Same author

Phase I trial of outpatient weekly docetaxel, carboplatin and concurrent thoracic radiation therapy for stage III unresectable non-small-cell lung cancer: a Vanderbilt cancer center affiliate network (VCCAN) trial.

Lung cancer (Amsterdam, Netherlands)·2001
Same author

Topoisomerase II inhibitors.

Cancer chemotherapy and biological response modifiers·2001
Same author

A randomized Phase II trial in patients with carcinoma of an unknown primary site.

Cancer·2001
Same journal

A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

Seminars in oncology·2026
Same journal

Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

Seminars in oncology·2026
Same journal

PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

Seminars in oncology·2026
Same journal

Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

Seminars in oncology·2026
Same journal

Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

Seminars in oncology·2026
Same journal

Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

Seminars in oncology·2026
See all related articles

Area of Science:

  • Pharmacology
  • Oncology
  • Molecular Biology

Background:

  • Etoposide, a podophyllotoxin derivative, exhibits significant antitumor activity against various human cancers, including lymphomas, germ cell tumors, and small cell lung cancer.
  • Its mechanism of action involves inducing DNA strand breaks via a complex with DNA and topoisomerase II.
  • Etoposide is characterized by a volume of distribution of 5-17 L/m2 and high plasma protein binding (94% bound, 6% free fraction).

Purpose of the Study:

  • To review the pharmacokinetic properties of etoposide, including its metabolism, distribution, and excretion.
  • To discuss mechanisms of etoposide resistance, particularly those involving membrane transport.
  • To highlight the variability in etoposide pharmacokinetics and explore correlations between plasma concentrations and toxicity for dose optimization.

Related Experiment Videos

Main Methods:

  • Literature review of etoposide's pharmacological and pharmacokinetic properties.
  • Analysis of studies investigating etoposide metabolism and excretion pathways (renal and biliary).
  • Examination of research on etoposide resistance mechanisms and pharmacokinetic variability in patients.

Main Results:

  • Etoposide undergoes metabolism, with several metabolites identified or proposed.
  • Acquired resistance to etoposide can occur through alterations in membrane transport mechanisms.
  • Significant intrapatient variability in pharmacokinetic parameters is observed for both intravenous and oral administration.
  • Renal excretion accounts for 30-40% of unchanged intravenous etoposide; biliary excretion is minimal.
  • Oral etoposide bioavailability averages 50% but shows considerable inter- and intrapatient variability, decreasing with higher doses.

Conclusions:

  • Understanding etoposide's pharmacokinetics, metabolism, and resistance mechanisms is crucial for effective cancer treatment.
  • The significant variability in etoposide bioavailability and disposition necessitates careful dosing and monitoring.
  • Correlating etoposide plasma concentrations with toxicity, such as myelosuppression, may lead to optimized therapeutic strategies and improved patient outcomes.